• Larimar Therapeutics Announces Upcoming Scientific Conference Presentations

    来源: Nasdaq GlobeNewswire / 02 6月 2022 08:00:02   America/New_York

    BALA CYNWYD, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced upcoming presentations at the United Mitochondrial Disease Foundation Mitochondrial Medicine 2022 meeting and XXIV World Congress International Society for Heart Research. Details on the presentations are shown below.

    United Mitochondrial Disease Foundation Mitochondrial Medicine 2022

    Conference Location:AAA 4-Diamond JW Marriott Phoenix Desert Ridge Resort & Spa (Phoenix, Arizona)
    Presentation Title:Frataxin (FXN) Promotes the Expression of Neuronal Differentiation Markers: Effect of FXN Supplementation in a Neurodegeneration Model
    Presentation Format:Oral
    Presenting Author:Matthew Baile, Ph.D., Senior Research Investigator, Larimar Therapeutics
    Presentation Date:June 9, 2022
    Presentation Time:5:30 PM PDT

    During the presentation, Dr. Baile will discuss preclinical studies performed in in vitro and in vivo disease models that evaluated CTI-1601’s effects on gene expression and neurodegeneration.

    XXIV World Congress International Society for Heart Research

    Conference Location:Mercure Hotel MOA Berlin (Berlin, Germany)
    Presentation Title:Lipidomics Insights into Mitochondrial Disorders & Heart Failure
    Presentation Format:Oral
    Presenting Author:Christine Des Rosiers, Ph.D., Director, Metabolomic Laboratory & Platform, Montreal Heart Institute; Honorary and Associate Professor, Department of Nutrition, Université de Montréal
    Presentation Date:June 15, 2022
    Presentation Time:To take place during the congress’s “Multi-omics Approaches to Understand Heart Failure” symposium, which is scheduled for 9:45 AM – 11:45 AM CEST

    During the presentation, Dr. Des Rosiers will present the results of collaborative studies with Larimar that analyzed the lipidomic profiles of samples from healthy individuals and from patients with Friedreich's ataxia that were untreated or treated with CTI-1601 during Larimar’s Phase 1 multiple-ascending dose clinical trial.

    About Larimar Therapeutics
    Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

    Investor Contact:
    Joyce Allaire
    LifeSci Advisors
    jallaire@lifesciadvisors.com
    (212) 915-2569

    Company Contact:
    Michael Celano
    Chief Financial Officer
    mcelano@larimartx.com
    (484) 414-2715


    Primary Logo

分享